CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease: Mendelian Randomization Investigation Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral Anticoagulants SR-B1 Drives Endothelial Cell LDL Transcytosis via DOCK4 to Promote Atherosclerosis Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease : A Special Report From the American Heart Association and American College of Cardiology Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI

Editorial2017 Oct 1;2(10):1061-1062.

JOURNAL:JAMA Cardiol. Article Link

What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?

Ruel M, Verma S, Bhatt DL. Keywords: PCI; CABG; repeat revascularization

ABSTRACT

Over the last months, 2 major trials and several meta-analyses have been published on the treatment of stable, unprotected left main coronary artery stenosis. Currently, North American and European guidelines for the treatment of left main stenosis indicate a class I recommendation for the performance of coronary artery bypass grafting (CABG). They also indicate a class IIa to III (North American) or a class I to III (European) recommendation for percutaneous coronary intervention (PCI), depending on the complexity of the coronary anatomy as determined by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score.